vs
Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $94.4M, roughly 1.9× Caesarstone Ltd.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -93.1%, a 94.8% gap on every dollar of revenue. Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -57.8%).
Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CSTE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.4M | $177.4M |
| Net Profit | $-87.9M | $2.9M |
| Gross Margin | 15.5% | — |
| Operating Margin | -87.2% | 3.9% |
| Net Margin | -93.1% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-2.55 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $94.4M | $196.9M | ||
| Q3 25 | $345.4M | $179.5M | ||
| Q2 25 | $237.7M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $436.7M | $168.6M | ||
| Q2 24 | $294.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-87.9M | — | ||
| Q3 25 | $-18.5M | $5.4M | ||
| Q2 25 | $-14.3M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-57.4M | $-143.5M | ||
| Q2 24 | $-56.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 15.5% | 79.5% | ||
| Q3 25 | 22.5% | 80.9% | ||
| Q2 25 | 23.7% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 15.7% | 76.9% | ||
| Q2 24 | 14.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -87.2% | 1.2% | ||
| Q3 25 | -5.5% | 3.5% | ||
| Q2 25 | -6.2% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -12.6% | -82.8% | ||
| Q2 24 | -18.0% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -93.1% | — | ||
| Q3 25 | -5.4% | 3.0% | ||
| Q2 25 | -6.0% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -13.1% | -85.1% | ||
| Q2 24 | -19.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-2.55 | $0.05 | ||
| Q3 25 | $-0.54 | $0.12 | ||
| Q2 25 | $-0.41 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-1.67 | $-3.11 | ||
| Q2 24 | $-1.64 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.4M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.2M | $653.9M |
| Total Assets | $398.4M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $58.4M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $139.2M | $693.1M | ||
| Q3 25 | $271.6M | $727.2M | ||
| Q2 25 | $271.6M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $315.1M | $749.6M | ||
| Q2 24 | $315.1M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $398.4M | $1.3B | ||
| Q3 25 | $549.0M | $1.3B | ||
| Q2 25 | $549.0M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $579.9M | $1.5B | ||
| Q2 24 | $579.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.0M | — |
| Free Cash FlowOCF − Capex | $-47.1M | — |
| FCF MarginFCF / Revenue | -49.8% | — |
| Capex IntensityCapex / Revenue | 9.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $38.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-38.0M | $43.7M | ||
| Q3 25 | $35.0M | $60.8M | ||
| Q2 25 | $18.7M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $53.3M | $53.9M | ||
| Q2 24 | $25.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-47.1M | $43.5M | ||
| Q3 25 | $26.7M | $57.0M | ||
| Q2 25 | $14.3M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $44.6M | $49.8M | ||
| Q2 24 | $20.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -49.8% | 22.1% | ||
| Q3 25 | 7.7% | 31.7% | ||
| Q2 25 | 6.0% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 10.2% | 29.6% | ||
| Q2 24 | 7.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.6% | 0.1% | ||
| Q3 25 | 2.4% | 2.2% | ||
| Q2 25 | 1.8% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 1.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
